Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the effect of the non-availability of Lithyronine on the NHS on patients who have previously being prescribed that drug.

NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October.

We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to – including guidance on the usage of liothyronine.

Further information can be found at the following link:

https://www.engage.england.nhs.uk/consultation/items-routinely-prescribed/